Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 6,835 shares of Illumina stock in a transaction on Monday, November 5th. The shares were sold at an average price of $326.11, for a total value of $2,228,961.85. Following the completion of the transaction, the senior vice president now owns 17,126 shares in the company, valued at approximately $5,584,959.86. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Oene Mark Van also recently made the following trade(s):
- On Tuesday, September 4th, Oene Mark Van sold 1,091 shares of Illumina stock. The shares were sold at an average price of $354.18, for a total value of $386,410.38.
Shares of ILMN stock opened at $339.55 on Friday. The firm has a market cap of $47.44 billion, a P/E ratio of 84.89, a PEG ratio of 2.40 and a beta of 1.07. Illumina, Inc. has a twelve month low of $203.83 and a twelve month high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $350.00 price target on shares of Illumina in a research note on Tuesday, July 31st. Canaccord Genuity reiterated a “buy” rating and issued a $340.00 price target (up previously from $330.00) on shares of Illumina in a research note on Friday, July 27th. Barclays boosted their price objective on Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 24th. Finally, Citigroup boosted their price objective on Illumina from $330.00 to $345.00 and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $330.94.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Kaizen Advisory LLC lifted its holdings in Illumina by 161.0% during the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after buying an additional 227 shares during the period. Moneta Group Investment Advisors LLC lifted its holdings in Illumina by 2,670.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock worth $107,000 after buying an additional 9,345 shares during the period. Sun Life Financial INC lifted its holdings in Illumina by 152.5% during the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after buying an additional 241 shares during the period. Highstreet Asset Management Inc. acquired a new position in Illumina during the 3rd quarter worth about $112,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Illumina by 3,192.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after buying an additional 415 shares during the period. 89.90% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) SVP Oene Mark Van Sells 6,835 Shares” was published by WKRB News and is the property of of WKRB News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/09/illumina-inc-ilmn-svp-oene-mark-van-sells-6835-shares.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.